ArticleSchizophrenia bulletin open2026
The Global Burden of Schizophrenia: Findings from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study.
Article in Schizophrenia bulletin open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acoustic Features of Sustained Phonation for Schizophrenia Classification: A Feasibility Study.Sensors (Basel, Switzerland) · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
Abstract
Background and Hypothesis: We utilized data from the 2021 Global Burden of Disease (GBD) Study to (i) provide estimates of the incidence, prevalence, and illness-related burden associated with schizophrenia; (2) examine how these rates have changed from 1990 to 2021; and (3) explore the association of these rates with several country-level variables (eg, access/quality of healthcare systems). Study Design: The GBD study provides estimates for the incidence, prevalence, and disability-adjusted life years (DALYs) associated with 371 illness, injuries, and risk factors by age and sex across 204 countries and territories. We examined data from the GBD 2021 study to describe the global epidemiology of schizophrenia as well as the association between metrics of schizophrenia epidemiology and country-level variables previously associated with these metrics. Study Results: In 2021, the global age-standardized incidence, prevalence, and DALY rates were 15.4, 277.7, and 177.8 per 100 000 individuals, respectively. Between 1990 and 2021, global incidence rates (both age-standardized and crude) declined, whereas crude prevalence and DALY rates per 100 000 increased and age-standardized prevalence and DALYs remained unchanged. However, these findings varied by age, gender, and geography. Changes in country-level variables between 1990-2021 (eg, alcohol use and per capita income) were associated with changes in incidence, prevalence, and DALY rates over this same time period. Conclusions: Schizophrenia remains a significant health concern worldwide. Our results highlight the need for health systems to prepare to address the growing prevalence of schizophrenia which may be greatest among older adults, and especially older women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.